FINWIRES · TerminalLIVE
FINWIRES

AkzoNobel Kept at Buy as Berenberg Notes 'Good Way' to Invest in Potential Iran War De-escalation

By

-- Berenberg maintained its buy rating on AkzoNobel (AKZA.AS), saying the paint and coatings company's shares present a "good way to invest" in the potential de-escalation of the conflict in Iran.

"Paint and coatings names usually benefit when oil prices are lower, owing to the ability to expand margins with lower raw material costs. Every USD10/barrel share decline in oil price has historically been associated with a EUR3/share increase in AkzoNobel's share price. Oil futures curves foresee a USD20/barrel decline over the next two years to cUSD75/barrel. We remain Buy-rated, but trim our price target to EUR66 (from EUR75)," analysts said in a Tuesday note.

The research firm also highlighted the ongoing progress in the Dutch company's merger with US-based paint manufacturer Axalta Coating Systems, with analysts expecting the latter to help AkzoNobel with its cost management, an area the company has "struggled" with at times.

On the financials side, analysts reduced their EPS estimates for 2026 through 2028 to account for "modestly lower" volumes, particularly in Europe. Conversely, Berenberg raised its sales forecast for AkzoNobel over the same three-year period.

Related Articles

Asia

JCET's Q1 Profit Jumps 43%, Revenue Slips 2%

JCET's (SHA:600584) net profit attributable to shareholders in the first quarter jumped 43% to 290.3 million yuan from 203.4 million yuan a year earlier, according to a Shanghai bourse filing on Wednesday.Earnings per share rose 45% year on year to 0.16 yuan from 0.11 yuan.Operating revenue slipped 1.8% to 9.17 billion yuan from 9.34 billion yuan in the preceding year.The shares of the Chinese integrated circuit manufacturer dropped less than 3% during midday trade.

$SHA:600584
Asia

Update: G8 Education to Suspend Operation of Around 40 Centers, Shares Reach 16-Year Low

(Updates to add the stock movement in the sixth paragraph)G8 Education (ASX:GEM) plans to suspend the operation of around 40 of its centers as a result of an assessment of its network, according to a Wednesday Australian bourse filing.It will transition customers to one of the nearby centers and, where possible, redeploy team members. The firm will then consider longer-term options for those centers, including lease surrender, divestment, or other alternatives.The firm will also reorganize its support office structure and reduce its cost base.Its current spot occupancy as of April 24 came in at 56.4%, down 7% year-over-year, while year-to-date occupancy was 56.1%, down 7.9% versus the prior corresponding period.Occupancy across the early childhood education and care sector is lower compared to previous years due to sustained affordability pressures, falling birth rates, increased long-day care supply, and confidence impacted by serious child safety incidents, the filing noted.Its shares fell 25% in recent trading on Wednesday, earlier reaching a 16-year low.

$ASX:GEM
Asia

Fosun Pharmaceutical Reports 14% Higher Profit in Q1

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.

$HKG:2196$SHA:600196